A phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

Everett E. Vokes, Boon C. Goh, Donna Bertucci, Nicholas J. Vogelzang, Sridhar Mani, Mark J. Ratain

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m2 every 3 weeks. Paclitaxel also has a broad spectrum of activity. A Phase I study of both agents in combination therapy was conducted. METHODS. Eligible patients had refractory solid tumors and a Cancer and Leukemia Group B performance status of 0 to 2. Cohorts of patients were treated with escalating doses of raltitrexed as a 15-minute intravenous infusion immediately followed by 175 mg/m2 of paclitaxel administered over 3 hours. Dose-limiting toxicity was defined as World Health Organization Grade 4 neutropenia with fever, Grade 4 thrombocytopenia requiring platelet transfusion, a nonhematologic toxicity of Grade 3 or higher (excluding nausea, emesis, and alopecia), or failure of toxicities to recover to Grade 1 or lower within 21 days after causing a dose delay. RESULTS. A total of 33 patients enrolled in the study. Raltitrexed was escalated in increments of 0.5 mg/m2, from 0.5 mg/m2 to the recommended Phase II dose of 3 mg/m2. Dose-limiting toxicity first was observed at a raltitrexed dose of 2 mg/m2. At a dose of 3 mg/m2, dose-limiting neutropenia was observed in 2 of 12 patients. Diarrhea was the other dose-limiting toxicity. Two patients achieved a partial response (one patient with carcinoma of the head and neck and another with gallbladder carcinoma). CONCLUSIONS. The authors conclude that raltitrexed and paclitaxel may be administered in combination at their respective single agent Phase II doses. Phase II testing of this combination is indicated.

Original languageEnglish (US)
Pages (from-to)528-532
Number of pages5
JournalCancer
Volume86
Issue number3
DOIs
StatePublished - Aug 1 1999
Externally publishedYes

Fingerprint

Paclitaxel
Neoplasms
Neutropenia
Carcinoma
Thymidylate Synthase
Platelet Transfusion
Alopecia
Gallbladder
Intravenous Infusions
Nausea
Vomiting
raltitrexed
Diarrhea
Leukemia
Fever
Neck
Head
Breast Neoplasms
Lung

Keywords

  • Combination
  • Paclitaxel
  • Phase I
  • Raltitrexed

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. / Vokes, Everett E.; Goh, Boon C.; Bertucci, Donna; Vogelzang, Nicholas J.; Mani, Sridhar; Ratain, Mark J.

In: Cancer, Vol. 86, No. 3, 01.08.1999, p. 528-532.

Research output: Contribution to journalArticle

Vokes, Everett E. ; Goh, Boon C. ; Bertucci, Donna ; Vogelzang, Nicholas J. ; Mani, Sridhar ; Ratain, Mark J. / A phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. In: Cancer. 1999 ; Vol. 86, No. 3. pp. 528-532.
@article{b66c35bf5aa24404b57491f122cb769b,
title = "A phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors",
abstract = "BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m2 every 3 weeks. Paclitaxel also has a broad spectrum of activity. A Phase I study of both agents in combination therapy was conducted. METHODS. Eligible patients had refractory solid tumors and a Cancer and Leukemia Group B performance status of 0 to 2. Cohorts of patients were treated with escalating doses of raltitrexed as a 15-minute intravenous infusion immediately followed by 175 mg/m2 of paclitaxel administered over 3 hours. Dose-limiting toxicity was defined as World Health Organization Grade 4 neutropenia with fever, Grade 4 thrombocytopenia requiring platelet transfusion, a nonhematologic toxicity of Grade 3 or higher (excluding nausea, emesis, and alopecia), or failure of toxicities to recover to Grade 1 or lower within 21 days after causing a dose delay. RESULTS. A total of 33 patients enrolled in the study. Raltitrexed was escalated in increments of 0.5 mg/m2, from 0.5 mg/m2 to the recommended Phase II dose of 3 mg/m2. Dose-limiting toxicity first was observed at a raltitrexed dose of 2 mg/m2. At a dose of 3 mg/m2, dose-limiting neutropenia was observed in 2 of 12 patients. Diarrhea was the other dose-limiting toxicity. Two patients achieved a partial response (one patient with carcinoma of the head and neck and another with gallbladder carcinoma). CONCLUSIONS. The authors conclude that raltitrexed and paclitaxel may be administered in combination at their respective single agent Phase II doses. Phase II testing of this combination is indicated.",
keywords = "Combination, Paclitaxel, Phase I, Raltitrexed",
author = "Vokes, {Everett E.} and Goh, {Boon C.} and Donna Bertucci and Vogelzang, {Nicholas J.} and Sridhar Mani and Ratain, {Mark J.}",
year = "1999",
month = "8",
day = "1",
doi = "10.1002/(SICI)1097-0142(19990801)86:3<528::AID-CNCR23>3.0.CO;2-R",
language = "English (US)",
volume = "86",
pages = "528--532",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - A phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

AU - Vokes, Everett E.

AU - Goh, Boon C.

AU - Bertucci, Donna

AU - Vogelzang, Nicholas J.

AU - Mani, Sridhar

AU - Ratain, Mark J.

PY - 1999/8/1

Y1 - 1999/8/1

N2 - BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m2 every 3 weeks. Paclitaxel also has a broad spectrum of activity. A Phase I study of both agents in combination therapy was conducted. METHODS. Eligible patients had refractory solid tumors and a Cancer and Leukemia Group B performance status of 0 to 2. Cohorts of patients were treated with escalating doses of raltitrexed as a 15-minute intravenous infusion immediately followed by 175 mg/m2 of paclitaxel administered over 3 hours. Dose-limiting toxicity was defined as World Health Organization Grade 4 neutropenia with fever, Grade 4 thrombocytopenia requiring platelet transfusion, a nonhematologic toxicity of Grade 3 or higher (excluding nausea, emesis, and alopecia), or failure of toxicities to recover to Grade 1 or lower within 21 days after causing a dose delay. RESULTS. A total of 33 patients enrolled in the study. Raltitrexed was escalated in increments of 0.5 mg/m2, from 0.5 mg/m2 to the recommended Phase II dose of 3 mg/m2. Dose-limiting toxicity first was observed at a raltitrexed dose of 2 mg/m2. At a dose of 3 mg/m2, dose-limiting neutropenia was observed in 2 of 12 patients. Diarrhea was the other dose-limiting toxicity. Two patients achieved a partial response (one patient with carcinoma of the head and neck and another with gallbladder carcinoma). CONCLUSIONS. The authors conclude that raltitrexed and paclitaxel may be administered in combination at their respective single agent Phase II doses. Phase II testing of this combination is indicated.

AB - BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m2 every 3 weeks. Paclitaxel also has a broad spectrum of activity. A Phase I study of both agents in combination therapy was conducted. METHODS. Eligible patients had refractory solid tumors and a Cancer and Leukemia Group B performance status of 0 to 2. Cohorts of patients were treated with escalating doses of raltitrexed as a 15-minute intravenous infusion immediately followed by 175 mg/m2 of paclitaxel administered over 3 hours. Dose-limiting toxicity was defined as World Health Organization Grade 4 neutropenia with fever, Grade 4 thrombocytopenia requiring platelet transfusion, a nonhematologic toxicity of Grade 3 or higher (excluding nausea, emesis, and alopecia), or failure of toxicities to recover to Grade 1 or lower within 21 days after causing a dose delay. RESULTS. A total of 33 patients enrolled in the study. Raltitrexed was escalated in increments of 0.5 mg/m2, from 0.5 mg/m2 to the recommended Phase II dose of 3 mg/m2. Dose-limiting toxicity first was observed at a raltitrexed dose of 2 mg/m2. At a dose of 3 mg/m2, dose-limiting neutropenia was observed in 2 of 12 patients. Diarrhea was the other dose-limiting toxicity. Two patients achieved a partial response (one patient with carcinoma of the head and neck and another with gallbladder carcinoma). CONCLUSIONS. The authors conclude that raltitrexed and paclitaxel may be administered in combination at their respective single agent Phase II doses. Phase II testing of this combination is indicated.

KW - Combination

KW - Paclitaxel

KW - Phase I

KW - Raltitrexed

UR - http://www.scopus.com/inward/record.url?scp=0033178968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033178968&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990801)86:3<528::AID-CNCR23>3.0.CO;2-R

DO - 10.1002/(SICI)1097-0142(19990801)86:3<528::AID-CNCR23>3.0.CO;2-R

M3 - Article

VL - 86

SP - 528

EP - 532

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -